No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostate cancer

Prostate

Volumn 59, Issue 4, 2004, Pages 393-400

  Platz, Elizabeth A ^a,b,c   De Marzo, Angelo M ^b,c   Erlinger, Thomas P ^a,c   Rifai, Nader ^d   Visvanathan, Kala ^a,b   Hoffman, Sandra C ^a   Helzlsouer, Kathy J ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

C reactive protein; Cohort; Prostate cancer; Risk

Indexed keywords

C REACTIVE PROTEIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; SENSITIVITY ANALYSIS; UNITED STATES;

AGED; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; HUMANS; IMMUNOASSAY; INFLAMMATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 2442651474     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10368     Document Type: Article

References (28)

1. Gardner WAJ, Bennett BD. The prostate - Overview: Recent insights and speculations. Monogr Pathol 1992;34:129-148.
2. Platz EA. Prostatitis and prostate cancer. New Dev Prostate Cancer Treat 1998;3:71-73.
3. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 1999;155:1985-1992.
4. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-867.
5. Castell JV, Gomez-Lechon MJ, David M, Hirano T, Kishimoto T, Heinrich PC. Recombinant human interleukin-6 (IL-6/BSF-2/ HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 1988;232:347-350.
6. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998;128:127-137.
7. Block G, Hartman AM, Naughton D. A reduced dietary questionnaire: Development and validation. Epidemiology 1990;1:58-64.
8. National Institutes of Health, National Heart, Lung and Blood Institute. Clinical Guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report. Obes Res 1998;6:51S-209S.
9. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Ciqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
10. Trautner K, Cooper EH, Haworth S, Ward AM. An evaluation of serum protein profiles in the long-term surveillance of prostatic cancer. Scand J Urol Nephrol 1980;14:143-149.
11. McMillan DC, Talwar D, Sattar N, Underwood M, O'Reilly DS, McArdle C. The relationship between reduced vitamin antioxidant concentrations and the system inflammatory response in patients with common solid tumours. Clin Nutr 2002;21:161-164.
12. Latif Z, McMillan DC, Wallace AM, Sattar N, Mir K, Jones G, Underwood MA. The relationship of circulating insulin-like growth factor 1, its binding protein-3, prostate specific antigen, and C-reactive protein with disease stage in prostate cancer. Br J Urol 2002;89:396-399.
13. Chung TDK, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999;38:199-207.
14. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001;159:2159-2165.
15. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001;58:1008-1015.
16. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000;6:2702-2706.
17. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999;41:127-133.
18. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-b1 in patients with metastatic prostatic carcinoma. J Urol 1999;161:182-187.
19. Twillie DA, Eisenberger MA, Carducci MA, Hsieh WS, Kim WY, Simons JW. Interleukin-6: A candidate mediator of human prostate cancer morbidity. Urology 1995;45:542-549.
20. Wise GJ, Marella VK, Talluri G, Shirazian D. Cytokine variations in patients with hormone treated prostate cancer. J Urol 2000; 164:722-725.
21. Erlinger T, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. (This paper is under review of revisions by the journal decision is imminent, early next weak).
22. Rifai N, Furing JE, Lee IM, Manson JE, Ridker PM. Is C-reactive protein specific for vascular disease in women? Ann Intern Med 2002;136:529-533.
23. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997;82:4196-4200.
24. Lewis MR, Callas PW, Jenny NS, Tracy RP. Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples. Thromb Haemost 2001;86:1495-1500.
25. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference intervals and epidemiological applications. Clin Chem 1997;43:52-58.
26. de Maat MPM, de Bart ACW, Hennis BC, Meijer P, Havelaar AD, Mulder PGH, Kluft C. Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in health, young volunteers and patients with angina pectoris. Arterioscler Thromb Vasc Biol 1996;16:1156-1162.
27. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001;47:444-450.
28. Kayaba K, Ishikawa S, Gotoh T, Nago N, Kajii E, Nakamura Y, Kario K. Five-year intra-individual variability in C-reactive protein levels in a Japanese population-based study: The Jichi Medical School Cohort Study at Yamato, 1993-1998. Jpn Circ J 2000;64:303-308.